Table 1.
Summary of the literature including current series
| First author, year | Number of patients | Mean age, years | Gender M/F | Indication | Technical success, % | Complications | Follow-up | Stent type | Filter | Angioplasty | Antiplatelet | In-stent stenosis | Recurrence rate,% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elmokadem [9], 2016 | 2 | 38.5 | 1/1 | Recurrent ischemic strokes in web distribution | 100 | None | 8 months | Xact | 1 yes, 1 no | 1 yes, 1 no | Aspirin 81 mg, Clopidogrel 75 mg | None | 0 |
| Lenck [4], 2014 | 2 | 47.5 | 0/2 | Recurrent ischemic strokes in web distribution | 100 | None | 8.5 years | NA | NA | No | Aspirin 81 mg, Clopidogrel 75 mg | None | 0 |
| Martinez-Perez [10], 2017 | 1 | 47 | 0/1 | LVO | 100 | None | 6 months | NA | NA | NA | Aspirin 81 mg, Clopidogrel 75 mg | None | 0 |
| Haussen [8], 2017 | 16 | NA | NA | Stroke/TIA or recurrent stroke/TIA | 100 | None | 6 months | NA | NA | NA | DAPT | None | 0 |
| Current study | 4 | 44 | 1/3 | Recurrent ischemic strokes or LVO | 100 | Bradycardia in 3 patients | 9 months | Wallstent and Protégé | 2 yes, 2 no | No | Aspirin 81 mg, Ticagrelor 180 mg | None | 0 |
NA, not available; LVO, large-vessel occlusion; TIA, transient ischemic attack.